HPV &amp; head and neck cancer: a descriptive update

Goon, Peter; Stanley, Margaret; Ebmeyer, Jörg; Steinsträßer, L.; Upile, Tahwinder; Jerjes, Waseem; Bernal‐Sprekelsen, Manuel; Görner, Martin; Sudhoff, Holger

doi:10.1186/1758-3284-1-36

Cited by 175 publications

(164 citation statements)

References 59 publications

Supporting

Mentioning

153

Contrasting

Unclassified

Order By: Relevance

“…These findings were in agreement with the study that reported, HPV prevalence was 35.6% in oropharyngeal cancers, 23.5% in oral cancers and 24.0% in laryngeal cancers (Goon, et al, 2009). Nevertheless, many studies have suggested that tobacco use and alcohol consumption increase the risk of head and neck cancer (Coelho, 2012;Zhou et al, 2012).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16^INK4AImmunostaining

Ahmed¹,

Mustafa²,

Warille³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

“…Several authors have emphasized that a hallmark of the presence of HPV in cancer could be found in p16 nuclear or cytoplasmic overexpression, so that p16 could be considered a useful surrogate marker for HPV (Gillespie et al, 2009;Goon et al, 2009).…”

Section: Introductionmentioning

confidence: 99%

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16^INK4AImmunostaining

Ahmed¹,

Mustafa²,

Warille³

2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The human papillomavirus (HPV) is the aetiological cause of several benign and malignant tumors 1, 2, 3. Although recurrent respiratory papillomatosis (RRP) is a rare disease, there is severe morbidity and occasional mortality.…”

Section: Introductionmentioning

confidence: 99%

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Goon

Scholtz²,

Sudhoff³

2017

Laryngoscope Investig Oto

View full text Add to dashboard Cite

ObjectivesRecurrent respiratory papillomatosis (RRP) is a rare disease, but one with severe morbidity and occasional mortality. The aetiological agent is human papillomavirus (HPV), and HPV types 6 and 11 account for over 90% of all cases. In the active phase of the disease, patients require multiple hospital admissions for surgical removal or ablation of these benign tumors, which are likely to obstruct the airways if left unchecked. Long‐term sequelae include scarring of the vocal cords, change in voice timbre, or even muteness if a tracheostomy is required. The aim of this study was to determine if adjuvant vaccination with the quadrivalent HPV L1 vaccine (Gardasil™) would decrease numbers of surgical treatments post‐vaccination.MethodsA prospective pilot study following a cohort of 12 RRP patients, all of whom gave fully informed consent to participate. All patients had their papillomas typed and if they were found to have types 6 or 11, were vaccinated at the time of first surgical treatment in the hospital, according to the manufacturer's protocols. Patients were followed up closely with 3 or 6 month follow‐up visits. Standard surgical treatments were given and were not affected by whether they participated in the study.ResultsWe found a >7‐fold decrease in the incidence rates of papillomatosis requiring surgical intervention from the pre‐vaccination period (47.44/1000 patient‐months) compared to the post‐vaccination period (6.71/1000 patient‐months).DiscussionSurgical treatments for RRP are robust markers for papillomata which require treatment because of the dangers of obstruction of the airway. Despite the small size of this cohort (due to the rarity of this disease), the data suggests that adjuvant use of quadrivalent HPV L1 vaccine imparts significant benefit to this group of patients. A large multi‐center randomized placebo controlled trial is required to definitively establish whether this hypothesis is true and can become the new standard of therapy.Level of Evidence3b

show abstract

“…HNSCC, the sixth most common cancer diagnosed worldwide and the eighth most common cause of cancer death (2), is frequently associated with human papillomavirus (HPV) infection (3,4). Depending on the anatomic site of the tumor, HPV prevalence is estimated at 23-36% (5). HPV-positive HNSCCs form a distinct subset of HNCs that differs from HPV-negative HNSCCs in tumor biology and clinical characteristics, including superior clinical outcomes (6)(7)(8)(9).…”

mentioning

confidence: 99%

Characterization of HPV and host genome interactions in primary head and neck cancers

Parfenov¹,

Pedamallu²,

Gehlenborg³

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

342

474

View full text Add to dashboard Cite

Previous studies have established that a subset of head and neck tumors contains human papillomavirus (HPV) sequences and that HPV-driven head and neck cancers display distinct biological and clinical features. HPV is known to drive cancer by the actions of the E6 and E7 oncoproteins, but the molecular architecture of HPV infection and its interaction with the host genome in head and neck cancers have not been comprehensively described. We profiled a cohort of 279 head and neck cancers with next generation RNA and DNA sequencing and show that 35 (12.5%) tumors displayed evidence of high-risk HPV types 16, 33, or 35. Twentyfive cases had integration of the viral genome into one or more locations in the human genome with statistical enrichment for genic regions. Integrations had a marked impact on the human genome and were associated with alterations in DNA copy number, mRNA transcript abundance and splicing, and both inter-and intrachromosomal rearrangements. Many of these events involved genes with documented roles in cancer. Cancers with integrated vs. nonintegrated HPV displayed different patterns of DNA methylation and both human and viral gene expressions. Together, these data provide insight into the mechanisms by which HPV interacts with the human genome beyond expression of viral oncoproteins and suggest that specific integration events are an integral component of viral oncogenesis.cancer | head and neck | papilloma virus | genome rearrangement | integration sites H ead and neck cancer (HNC) is a heterogeneous group of tumors characterized by a common anatomic origin, and most such tumors develop from within the mucosa and are classified as head and neck squamous cell carcinomas (HNSCCs) (1). HNSCC, the sixth most common cancer diagnosed worldwide and the eighth most common cause of cancer death (2), is frequently associated with human papillomavirus (HPV) infection (3, 4). Depending on the anatomic site of the tumor, HPV prevalence is estimated at 23-36% (5). HPV-positive HNSCCs form a distinct subset of HNCs that differs from HPV-negative HNSCCs in tumor biology and clinical characteristics, including superior clinical outcomes (6-9).The molecular pathogenesis of HPV-driven HNSCC also seems distinct from HPV-negative tumors, with previous studies showing a divergent spectrum of alterations in gene expression, mutations, amplifications, and deletions as well as distinct epigenome alterations (10-15). HPV is known to drive tumorigenesis through the actions of its major oncoproteins E6 and E7, which target numerous cellular pathways, including inactivation of p53 and the retinoblastoma (Rb) protein (16-18). Together with E5, they also play an important role in immune evasion, being involved in both innate and adaptive immunity (19,20).Initially after infection, HPV is identified in circular extrachromosomal particles or episomes. A critical step in progression to cancer is the integration of viral DNA into the host cell Significance A significant proportion of head and neck cancer is driven by human papil...

show abstract

HPV & head and neck cancer: a descriptive update

Cited by 175 publications

References 59 publications

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16^INK4AImmunostaining

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16^INK4AImmunostaining

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Characterization of HPV and host genome interactions in primary head and neck cancers

Contact Info

Product

Resources

About

HPV & head and neck cancer: a descriptive update

Cited by 175 publications

References 59 publications

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16INK4AImmunostaining

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16INK4AImmunostaining

Recurrent respiratory papillomatosis (RRP)–time for a reckoning?

Characterization of HPV and host genome interactions in primary head and neck cancers

Contact Info

Product

Resources

About

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16^INK4AImmunostaining

Human Papilloma Virus Attributable Head and Neck Cancer in the Sudan Assessed by p16^INK4AImmunostaining